Amphastar Pharmaceuticals, Inc
NASDAQ:AMPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amphastar Pharmaceuticals, Inc
NASDAQ:AMPH
|
US |
|
Banyan Tree Holdings Ltd
F:1O7
|
SG |
|
D
|
DBS Group Holdings Ltd
XMUN:DEVL
|
SG |
Intrinsic Value
The intrinsic value of Amphastar Pharmaceuticals, Inc (AMPH) under the Base Case is 23.57 USD per share.
Compared with the current market price of 26 USD, the stock appears
Overvalued by 9% .
The intrinsic value is calculated using the DCF method. The model assumes revenue grows about 3% a year over the next five years, less than a third of its five-year pace of 16%. Operating margin ends at 24% by 2033, above its five-year average of 23%.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Amphastar Pharmaceuticals Does
Amphastar Pharmaceuticals makes and sells injectable, inhalation, and intranasal medicines that are used in hospitals, emergency care, and other clinical settings. Its products include both branded and generic drugs, along with active pharmaceutical ingredients and certain drug-device combinations. The company focuses on medicines that are often hard to manufacture and supply consistently, which gives it a role in the lower-cost end of the pharmaceutical market.
- Headquarters
- United States of America US
- Employees
- 1 976
- IPO date
- Jun 25, 2014
Revenue & Expenses Breakdown
Amphastar Pharmaceuticals, Inc
Earnings Waterfall
Amphastar Pharmaceuticals, Inc
The intrinsic value for Amphastar Pharmaceuticals, Inc (AMPH) under the Base Case is 23.57 USD.
Compared with the current market price of 26 USD, the stock appears Overvalued by 9% .